|Mr. Walter V. Klemp||Founder, Chairman, Pres & CEO||567.8k||N/A||1960|
|Mr. Jonathan P. Foster||Exec. VP & CFO||457.4k||N/A||1964|
|Dr. Donald H. Picker||Chief Scientific Officer||342.66k||N/A||1946|
|Dr. Waldemar Priebe||Co-Founder and Chairman of Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Robert C. Shepard||Chief Medical Officer||N/A||N/A||1952|
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin that is in Phase I/II clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) in the United States and Poland. The company's flagship immune/transcription modulator is WP1066, a STAT3 inhibitor, which is in Phase I clinical trial for the treatment of brain tumor, as well as to treat pancreatic cancer, AML, and glioblastoma. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma in Poland; and WP1732, an analog of WP1066 for the treatment of AML, pancreatic, and other cancers. The company's lead metabolism/glycosylation inhibitor compound is WP1122, a prodrug of 2-deoxyglucose to treat brain tumors and pancreatic cancer. In addition, it develops WP1234 for the treatment of pancreatic cancer. Further, the company engages in the preclinical development of other drug candidates, including other immune/transcription modulators and metabolism/glycosylation inhibitors. It has an agreement with the University of Iowa Pharmaceuticals for the development of a formulation for WP1732; collaboration with Dermin Sp. zoo for the development of WP1220; and collaboration with M.D. Anderson Cancer Center for the development of WP1732 and WP1066. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.
Moleculin Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.